Fotemustine
Clinical data | |
---|---|
Trade names | Mustophoran |
AHFS/Drugs.com | International Drug Names |
ATC code | L01AD05 (WHO) |
Identifiers | |
| |
CAS Number | 92118-27-9 |
PubChem (CID) | 104799 |
DrugBank | DB04106 |
ChemSpider | 94600 |
UNII | GQ7JL9P5I2 |
KEGG | D07255 |
ChEMBL | CHEMBL549386 |
ECHA InfoCard | 100.158.792 |
Chemical and physical data | |
Formula | C9H19ClN3O5P |
Molar mass | 315.691 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study[1] has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).
External links
- ↑ Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M (March 2004). "Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study". 22 (6): 1118–25. doi:10.1200/JCO.2004.04.165. PMID 15020614.
This article is issued from Wikipedia - version of the 8/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.